Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To perform indirect treatment comparisons of entrectinib versus alternative ROS1 fusion-positive non-small cell lung cancer treatments. Methods: Relevant studies with crizotinib and chemotherapy as comparators of interest identified by systematic literature review were selected for matching-adjusted indirect comparison by feasibility assessment. Matching was based on known prognostic/predictive factors and scenario analyses were used for unreported confounders in comparator trials. Results: Entrectinib yielded significantly better responses versus crizotinib in all scenarios (odds ratio [OR]: 2.43–2.74). Overall survival (hazard ratio: 0.47–0.61) and adverse event-related discontinuation (OR: 0.79–0.90) favored entrectinib. Progression-free survival was similar across treatments, except in one scenario. Conclusion: These results suggested improved outcomes with entrectinib versus crizotinib/chemotherapy and may help to make better informed treatment decisions.
Supplementary Material
File (suppl_file.docx)
- Download
- 145.29 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87–108 (2015).
2.
Planchard D, Popat S, Kerr K et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(5), 863–870 (2019).
3.
Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 5(1), 25–34 (2015).
4.
Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L. Biological therapies in nonsmall cell lung cancer. Eur. Respir. J. 49(3), 1601520 (2017).
5.
Clave S, Gimeno J, Munoz-Marmol AM et al. ROS1 copy number alterations are frequent in non-small cell lung cancer. Oncotarget 7(7), 8019–8028 (2016).
6.
Scheffler M, Schultheis A, Teixido C et al. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget 6(12), 10577–10585 (2015).
7.
Gou LY, Niu FY, Wu YL, Zhong WZ. Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population. Cancer 121(Suppl. 17), 3069–3079 (2015).
8.
Facchinetti F, Rossi G, Bria E et al. Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition. Cancer Treat. Rev. 55, 83–95 (2017).
9.
Dong J, Li B, Lin D, Zhou Q, Huang D. Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front. Pharmacol. 10(230), 230 (2019).
10.
Fischer H, Ullah M, De La Cruz C et al. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro-Oncol. 22 (6), 819–829 (2020).
11.
Menichincheri M, Ardini E, Magnaghi P et al. Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J. Med. Chem. 59(7), 3392–3408 (2016).
12.
Coccia M. Path-breaking target therapies for lung cancer and a far-sighted health policy to support clinical and cost effectiveness. Health Pol. Technol. 3, 74–82 (2014).
13.
Morabito A. The evolution of the treatment of advanced NSCLC. Recenti Progressi Medicina 107(10), 510–514 (2016).
14.
Yu HA, Riely GJ. Second generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J. Natl. Compr. Canc. Netw. 11(2), 161–169 (2013).
15.
Chan BA, Hughes BGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl. Lung Cancer Res. 4(1), 36–54 (2015).
16.
Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368(25), 2385–2394 (2013).
• Crizotinib demonstrated a superior efficacy to standard chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen.
17.
Karachaliou N, Fernandez-Bruno M, Bracht JWP, Rosell R. EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients. Transl. Cancer Res. 8(Suppl. 1), 23–47 (2019).
18.
Russo A, Lopes AR, Mccusker MG et al. New targets in lung cancer (excluding EGFR, ALK, ROS1). Curr. Oncol. Rep. 22(5), 48 (2020).
19.
Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371(21), 1963–1971 (2014).
• In a Phase I study expansion cohort, crizotinib showed marked antitumor activity (overall response rate 72.0%; median progression-free survival 19.2 months; median duration of response 17.6 months) in patients with advanced ROS1-rearranged non-small cell lung cancer.
20.
Ou SI, Zhu VW. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. Lung Cancer 130, 201–207 (2019).
21.
Patil T, Smith DE, Bunn PA et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J. Thorac. Oncol. 13(11), 1717–1726 (2018).
• Retrospective analysis of patients with stage IV ROS1 fusion-positive non-small cell lung cancer treated with crizotinib. More than a third (36%) of treatment-naive patients had central nervous system (CNS) metastases at diagnosis, and the CNS was the first and sole site of progression in 47% of patients on crizotinib treatment.
22.
Peters S, Camidge DR, Shaw AT et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377(9), 829–838 (2017).
23.
Doebele R, Ahn M, Siena S et al. OA02.01 Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 13(10), S321–S322 (2018).
24.
Drilon A, Siena S, Dziadziuszko R et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three Phase 1–2 trials. Lancet Oncol. 21(2), 261–270 (2020).
•• Entrectinib showed clinically meaningful (overall response rate 77.4%; median progression-free survival 19.0 months) and durable (median duration of response 24.6 months) efficacy in patients with ROS1 fusion-positive non-small cell lung cancer and was well tolerated with a manageable safety profile.
25.
Macfarland SP, Naraparaju K, Iyer R et al. Mechanisms of entrectinib resistance in a neuroblastoma xenograft model. Mol. Cancer Ther. 19(3), 920–926 (2020).
26.
Ku BM, Bae YH, Lee KY et al. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Invest. New Drugs 38, 360–368 (2020).
27.
National Institute for Health and Care Excellence (NICE). TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (2018). www.nice.org.uk/guidance/ta529.
28.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009).
29.
CRD's guidance for undertaking reviews in health care (2018). www.york.ac.uk/media/crd/Systematic_Reviews.pdf
30.
The Cochrane Collaboration Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] (2011). www.handbook.cochrane.org
31.
Downs S, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Commun. Health 52(6), 377–384 (1998).
32.
TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (2018). www.nice.org.uk/guidance/ta529 .
33.
Fedorov S. GetData Graph Digitizer version 2.26 (2020). www.getdata-graph-digitizer.com/
34.
Signorovitch JE, Wu EQ, Yu AP et al. Comparative effectiveness without head-to-head trials. PharmacoEconomics 28(10), 935–945 (2010).
35.
Signorovitch JE, Sikirica V, Erder MH et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940–947 (2012).
36.
Rosenbaum PR, RD B. The central role of the propensity score in observational studies for causal effects. Biometrika 70(1), 41–55 (1983).
37.
Wu YL, Yang JCH, Kim DW et al. Phase II study of crizotinib in east asian patients with ROS1-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36(14), 1405–1411 (2018).
•• In this Phase II study, crizotinib demonstrated clinically meaningful benefit (overall response rate 71.7%; median progression-free survival 15.9 months) and durable responses (median duration of response 19.7 months) in East Asian patients with ROS1-positive advanced non-small cell lung cancer.
38.
Drilon A, Barlesi F, De Braud F et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. Cancer Res. 79, Abst. n CT192 (2019).
•• In an integrated analysis of three Phase I/II trials, entrectinib was tolerable with a manageable safety profile and demonstrated efficacy (overall response rate 77.4%; median progression-free survival 19.0 months) in patients with ROS1 fusion-positive non-small cell lung cancer.
39.
Soria J-C, Tan DSW, Chiari R et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, Phase 3 study. Lancet 389(10072), 917–929 (2017).
• In this randomized, open-label, Phase III study, ceritinib showed a statistically significant improvement in median progression-free survival (16.6 months) versus chemotherapy (8.1 months; hazard ratio: 0.55; p < 0.00001) in untreated patients with stage IIIB/IV ALK-rearranged non-small cell lung cancer.
40.
Ou SH, Janne PA, Bartlett CH et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann. Oncol. 25(2), 415–422 (2014).
• Patients with advanced ALK-positive non-small cell lung cancer who continued crizotinib treatment beyond progression had a longer overall survival and showed higher rates of Eastern Cooperative Oncology Group PS 1/2 than those who did not continue crizotinib beyond progression.
41.
Fenchel K, Sellmann L, Dempke WC. Overall survival in non-small cell lung cancer-what is clinically meaningful? Transl. Lung Cancer Res. 5(1), 115–119 (2016).
42.
Hamada T, Kosumi K, Nakai Y, Koike K. Surrogate study endpoints in the era of cancer immunotherapy. Ann. Transl. Med. 6(Suppl. 1), S27 (2018).
43.
Wu YL, Zhou C, Liam CK et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the Phase III, randomized, open-label, ENSURE study. Ann. Oncol. 26(9), 1883–1889 (2015).
44.
Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoS ONE 14(1), e0209709 (2019).
Information & Authors
Information
Published In
Pages: 861 - 876
PubMed: 32648475
Copyright
© 2020 Paula Chu. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 24 April 2020
Accepted: 16 June 2020
Published online: 10 July 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0063
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Nadia Karim, David Waterhouse, Simon Jones, Björn Stollenwerk, Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare payer perspective , Journal of Medical Economics, 10.1080/13696998.2025.2604968, 29, 1, (77-92), (2026).
- Divyan Chopra, Zhiyi Lan, David M. Waterhouse, Jürgen Wolf, Enriqueta Felip, Hoora Moradian, Nadia Karim, Cynthia Obiozor, Björn Stollenwerk, Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation, Advances in Therapy, 10.1007/s12325-025-03259-8, 42, 9, (4300-4317), (2025).
- Jürgen Wolf, Sarah Goring, Adam Lee, Byoung Chul Cho, Alexander Drilon, Yong Yuan, Dieter Ayers, Greta Lozano-Ortega, Ellen E. Korol, Sarah G. Korpach, Madeleine Crabtree, Lavanya Huria, Christophe Y. Calvet, D. Ross Camidge, Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC, Cancers, 10.3390/cancers17050748, 17, 5, (748), (2025).
- Yongfeng Yu, Yun Fan, Xiaorong Dong, Juan Li, Yan Yu, Jun Zhao, Sha Tao, Yujun Chen, Mo Chen, Yueming Liu, Jiahui Xu, Qiaonan Zhu, Xichun Hu, Shun Lu, Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison, Lung Cancer, 10.1016/j.lungcan.2024.108018, 198, (108018), (2024).
- Monica Daigl, Seye Abogunrin, Felipe Castro, Sarah F McGough, Rachele Hendricks Sturrup, Cornelis Boersma, Keith R Abrams, Advancing the role of real-world evidence in comparative effectiveness research, Journal of Comparative Effectiveness Research, 10.57264/cer-2024-0101, 13, 12, (2024).
- Ibrahim M. Abbass, Daniel M. Sheinson, Anuj Shah, Adam Gondos, Sarika Ogale, Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung cancer, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2024.30.7.649, 30, 7, (649-659), (2024).
- Nalan Akyürek, Molecular Carcinogenesis of Lung Cancer, Airway Diseases, 10.1007/978-3-031-22483-6_59-1, (1011-1031), (2023).
- Essam A. Ali, Muzaffar Iqbal, Gamal A. E. Mostafa, Rashad Al Salahi, Development and Validation of an Ecofriendly, Rapid, Simple and Sensitive UPLC-MS/MS Method for Entrectinib Quantification in Plasma for Therapeutic Drug Monitoring, Separations, 10.3390/separations10090494, 10, 9, (494), (2023).
- Brigida Stanzione, Alessandro Del Conte, Elisa Bertoli, Elisa De Carlo, Alberto Revelant, Michele Spina, Alessandra Bearz, Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer, International Journal of Molecular Sciences, 10.3390/ijms241411495, 24, 14, (11495), (2023).
- Paul K. Paik, Boris M. Pfeiffer, Helene Vioix, Andrea Garcia, Maarten J. Postma, Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations, Advances in Therapy, 10.1007/s12325-022-02163-9, 39, 7, (3159-3179), (2022).